Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$364.75 2.89 (0.79)%
Market Cap 38.65B
07/16/18 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
June 2018 JPM Healthcare Conference & Financial Overviews
Regeneron Pharmaceuticals Q2 2018 Earnings Conference Call
Aug 2, 2018